Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | PLA2G10 | O15496 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12035252 | 0.86 | CTSS (0.42) | NOTUMPLA2G10ALDH1A1TSHRMTOR | |
| SCHEMBL9987033 | 0.82 | NOTUM (0.42) | NOTUMPLA2G10ALDH1A1TSHRF10 | |
| SCHEMBL9987982 | 0.81 | PDE4B (0.46) | NOTUMALDH1A1PIK3CDPIK3CGPIK3R1 | |
| SCHEMBL20703991 | 0.80 | PIK3CD (0.56) | PIK3CDPIK3CGPIK3R1PIK3R2 | |
| SCHEMBL20703992 | 0.80 | PIK3CD (0.56) | PIK3CDPIK3CGPIK3R1PIK3R2 | |
| SCHEMBL9986428 | 0.79 | PLA2G10 (0.40) | NOTUMPLA2G10ALDH1A1TSHRPIK3CD | |
| SCHEMBL9987350 | 0.77 | NOTUM (0.42) | NOTUMALDH1A1MTORPIK3CDHPGD | |
| SCHEMBL9987443 | 0.77 | NOTUM (0.42) | NOTUMALDH1A1MTORPIK3CDHPGD | |
| SCHEMBL9987078 | 0.77 | NOTUM (0.39) | NOTUMPLA2G10ALDH1A1TSHRHPGD | |
| SCHEMBL9987150 | 0.75 | NOTUM (0.36) | NOTUMPLA2G10ALDH1A1TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062055-B2 | Fused pyrrole derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-06-23 | — | — | US | disclosed |
| WO-2011163195-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110312979-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312979-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | PIK3R5, PIK3R4, PIK3CA | NOTUM 3369/4885PLA2G10 1465/4885ALDH1A1 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.